Conduit Pharmaceuticals (CDT) provides an R&D update on the development progress of pipeline assets AZD1656, AZD5658, and AZD5904. The ...

Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, ...

Last July, the agency placed a hold on the trial due to a chromatographic signal detected in a human ADME study of the ...

On the path of innovative R&D, by practicing the model of joint innovation and working closely with enterprises in the ...

The company plans to resume its CATT1 Phase 3 trial for type 1 diabetes after submitting a protocol amendment.

Tv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall durati ...

Shares of vTv Therapeutics rose after the Food and Drug Administration lifted a clinical hold on its diabetes treatment program. The stock gained 40% to $20.78 Monday morning. Shares have climbed ...

Cadisegliatin is an oral, liver selective glucokinase activator that's being investigated as an adjunctive treatment to insulin for type 1 diabetes. The company announced the Phase 3 trial in July.

Investing.com -- Shares of vTv Therapeutics Inc . (NASDAQ: VTVT) rose 15% after the company announced that the FDA has lifted the clinical hold on its Cadisegliatin program for diabetes. Trading had ...

Cadisegliatin is an oral, liver-selective glucokinase activator that has been generally well tolerated in over 500 subjects to date with up to six months of treatment. vTv Therapeutics expects to ...